Cargando…

Therapeutic revolution for inoperable stage III non-small cell lung cancer in the immune era

Detalles Bibliográficos
Autores principales:	Li, Jiakang, Xu, Jingyan, Yang, Mingyi, Zhou, Qing
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Compuscript 2022
Materias:	Perspective
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9196062/ https://www.ncbi.nlm.nih.gov/pubmed/35676755 http://dx.doi.org/10.20892/j.issn.2095-3941.2022.0254

Ejemplares similares

Immunotherapy in inoperable stage III non-small cell lung cancer: a review
por: Jain, Natasha A, et al.
Publicado: (2019)

Can LMWH improve the outcome of patients with inoperable stage III non-small cell lung cancer?
por: Kucukoner, Mehmet, et al.
Publicado: (2012)

Pattern-of-failure and salvage treatment analysis after chemoradiotherapy for inoperable stage III non-small cell lung cancer
por: Taugner, Julian, et al.
Publicado: (2020)

A Canadian Perspective on the Challenges for Delivery of Curative-Intent Therapy in Stage III Unresectable Non-Small Cell Lung Cancer
por: Brade, Anthony, et al.
Publicado: (2021)

Combined Radiomics–Clinical Model to Predict Radiotherapy Response in Inoperable Stage III and IV Non-Small-Cell Lung Cancer
por: Chen, Wenrui, et al.
Publicado: (2022)

Hypofractionated radiotherapy for medically inoperable stage I non‐small cell lung cancer
por: Jiang, Wei, et al.
Publicado: (2015)

Clinical Management and Outcome of Grade III Pneumonitis after Chemoradioimmunotherapy for Inoperable Stage III Non-Small Cell Lung Cancer—A Prospective Longitudinal Assessment
por: Kauffmann-Guerrero, Diego, et al.
Publicado: (2021)

Percutaneous Cryoablation for the Treatment of Medically Inoperable Stage I Non-Small Cell Lung Cancer
por: Yamauchi, Yoshikane, et al.
Publicado: (2012)

Hypofractionated Accelerated Concurrent Chemoradiotherapy in Inoperable Stage III Non-small Cell Lung Cancer: SOCCAR. A Large Single-Centre Experience
por: Patibandla, A., et al.
Publicado: (2020)

Real-World Experience of Patients with Inoperable, Stage III Non-small-Cell Lung Cancer Treated with Durvalumab after Chemoradiotherapy: Indian Experience
por: Noronha, Vanita, et al.
Publicado: (2020)

Clinical results of proton beam radiotherapy for inoperable stage III non-small cell lung cancer: a Japanese national registry study
por: Tatebe, Hitoshi, et al.
Publicado: (2023)

Efficacy and safety of particle therapy for inoperable stage II-III non-small cell lung cancer: a systematic review and meta-analysis
por: Chen, Yanliang, et al.
Publicado: (2023)

The Coming Primary Care Revolution
por: Ellner, Andrew L., et al.
Publicado: (2017)

Negativation of PD-L1 Postoperatively in Initially Inoperable Stage III Non-Small Cell Lung Cancer Treated with Pembrolizumab: Two Case Reports
por: Nasr, Fadi, et al.
Publicado: (2019)

Chemoradioimmunotherapy of inoperable stage III non-small cell lung cancer: immunological rationale and current clinical trials establishing a novel multimodal strategy
por: Käsmann, Lukas, et al.
Publicado: (2020)

Devolution of power, revolution in public health?
por: Katikireddi, Srinivasa Vittal, et al.
Publicado: (2017)

Planning target volume as a predictor of disease progression in inoperable stage III non-small cell lung cancer patients treated with chemoradiotherapy and concurrent and/or sequential immune checkpoint inhibition
por: Taugner, Julian, et al.
Publicado: (2021)

Concurrent/sequential versus sequential immune checkpoint inhibition in inoperable large stage III non-small cell lung cancer patients treated with chemoradiotherapy: a prospective observational study
por: Käsmann, Lukas, et al.
Publicado: (2023)

Results of systemic treatment of cutaneous melanoma in inoperable stage III and IV
por: Cybulska-Stopa, Bożena, et al.
Publicado: (2013)

Hypofractionated three-dimensional conformal radiotherapy for medically inoperable early stage non-small-cell lung cancer
por: Lee, Joo Ho, et al.
Publicado: (2013)

Percutaneous radiofrequency ablation for medically inoperable patients with clinical stage I non-small cell lung cancer
por: Liu, Baodong, et al.
Publicado: (2015)

Rationale for Combing Stereotactic Body Radiation Therapy with Immune Checkpoint Inhibitors in Medically Inoperable Early-Stage Non-Small Cell Lung Cancer
por: Chi, Alexander, et al.
Publicado: (2022)

Therapeutic management options for stage III non-small cell lung cancer
por: Yoon, Stephanie M, et al.
Publicado: (2017)

Evolving Therapeutic Scenario of Stage III Non-Small-Cell Lung Cancer
por: Baudoux, Nathalie, et al.
Publicado: (2023)

Organ-specific efficacy in advanced non-small cell lung cancer patients treated with first-line single-agent immune checkpoint inhibitors
por: Deng, Jiayi, et al.
Publicado: (2022)

Concurrent Chemoradiotherapy with Vinorelbine plus Split-Dose Cisplatin may be an Option in Inoperable Stage III Non-Small Cell Lung Cancer: A Single-Center Experience
por: Mertsoylu, Hüseyin, et al.
Publicado: (2015)

A phase II open-label multicenter study of gefitinib in combination with irradiation followed by chemotherapy in patients with inoperable stage III non-small cell lung cancer
por: Levy, Antonin, et al.
Publicado: (2016)

Implementation of durvalumab maintenance treatment after concurrent chemoradiotherapy in inoperable stage III non-small cell lung cancer (NSCLC)—a German radiation oncology survey
por: Käsmann, Lukas, et al.
Publicado: (2020)

Relationship between Treatment Plan Dosimetry, Toxicity, and Survival following Intensity-Modulated Radiotherapy, with or without Chemotherapy, for Stage III Inoperable Non-Small Cell Lung Cancer
por: Remmerts de Vries, Isabel F., et al.
Publicado: (2021)

Randomized phase II trial of S‐1 plus cisplatin or docetaxel plus cisplatin with concurrent thoracic radiotherapy for inoperable stage III non‐small cell lung cancer
por: Shimokawa, Tsuneo, et al.
Publicado: (2020)

Evolution or revolution? Changing the way science is published and communicated
por: Baum, Buzz, et al.
Publicado: (2019)

Absence of toxicity with hypofractionated 3-dimensional radiation therapy for inoperable, early stage non-small cell lung cancer
por: Faria, Sergio L, et al.
Publicado: (2006)

Radical cyberknife radiosurgery with tumor tracking: an effective treatment for inoperable small peripheral stage I non-small cell lung cancer
por: Collins, Brian T, et al.
Publicado: (2009)

Welcome to the revolution: COVID-19 and the democratization of spatial-temporal data
por: Koch, Tom
Publicado: (2021)

Real-world risk of brain metastases in stage III non-small cell lung cancer in the era of PET and MRI staging
por: Alhusaini, Saud, et al.
Publicado: (2023)

Whipple Grossing in the Era of New Staging: Should We Standardize?
por: Shi, Jiaqi, et al.
Publicado: (2019)

Definitive Bimodality Concurrent Chemoradiotherapy in Patients with Inoperable N2-positive Stage IIIA Non-small Cell Lung Cancer
por: Noh, Jae Myoung, et al.
Publicado: (2015)

Stereotactic Body Radiotherapy for Medically Inoperable Stage I-II Non–Small Cell Lung Cancer: The Mayo Clinic Experience
por: Hobbs, Corey J., et al.
Publicado: (2017)

Differential role of residual metabolic tumor volume in inoperable stage III NSCLC after chemoradiotherapy ± immune checkpoint inhibition
por: Unterrainer, Marcus, et al.
Publicado: (2021)

A phase I study of nedaplatin, pemetrexed and thoracic intensity-modulated radiotherapy for inoperable stage III lung adenocarcinoma
por: Lu, Yiyu, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_0273a1laq6m717l71qcirutaah